Show simple item record

dc.contributor.authorGennatas, S
dc.contributor.authorChamberlain, F
dc.contributor.authorCarter, T
dc.contributor.authorSlater, S
dc.contributor.authorCojocaru, E
dc.contributor.authorLambourn, B
dc.contributor.authorStansfeld, A
dc.contributor.authorTodd, R
dc.contributor.authorVerrill, M
dc.contributor.authorAli, N
dc.contributor.authorJones, RL
dc.contributor.authorSimmonds, P
dc.contributor.authorKeay, N
dc.contributor.authorMcCarty, H
dc.contributor.authorStrauss, S
dc.contributor.authorKaravasilis, V
dc.contributor.authorDileo, P
dc.contributor.authorBenson, C
dc.date.accessioned2022-02-03T11:16:38Z
dc.date.available2022-02-03T11:16:38Z
dc.date.issued2020-05-06
dc.identifier.citationClinical sarcoma research, 2020, 10 pp. 9 - ?
dc.identifier.issn2045-3329
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4995
dc.identifier.eissn2045-3329
dc.identifier.eissn2045-3329
dc.identifier.doi10.1186/s13569-020-00131-x
dc.identifier.doi10.1186/s13569-020-00131-x
dc.description.abstractBACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin alone. The recently presented phase III study of doxorubicin and olaratumab in advanced soft tissue sarcoma was discordant with this finding. METHODS: We performed a retrospective analysis of adult patients with advanced-/metastatic STS treated with at least two cycles of doxorubicin and olaratumab at eight sarcoma units across England and Northern Ireland between May 2017 and March 2019. RESULTS: 172 patients were evaluable and 40 patients (23.3%) had died at the time of analysis. Median ECOG performance status (PS) was 1. Median progression free survival (PFS) was 6.8 months (95% CI 5.9-7.7 months). Leiomyosarcoma was the most common histological subtype (75 patients, 43.6%), followed by liposarcomas (19, 11.0%). The mean number of cycles was 5 (doxorubicin range 2-6; olaratumab range 2-23). Two patients (1.2%) had a complete response and 34 (19.8%) had a partial response. 79 (45.9%) had stable and 58 (33.7%) progressive disease. 57 patients (33.1%) experienced grade ≥ 3 neutropenia and 7 patients (4.1%) grade ≥ 3 febrile neutropenia. Grade ≥ 3 anaemia was seen in 21 patients (12.2%). Grade ≥ 3 non-haematological toxicities were seen in 35 patients (20.3%). A clinically significant drop in left ventricular ejection fraction was seen in 6 patients (3.5%). 48 patients (27.9%) required a dose reduction. Overall survival (OS) is pending. CONCLUSIONS: Our results are in keeping with the phase III study findings: response rate, PFS and OS were similar to those reported in the phase III ANNOUNCE trial.
dc.formatElectronic-eCollection
dc.format.extent9 - ?
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleReal-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
dc.typeJournal Article
dcterms.dateAccepted2020-04-25
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1186/s13569-020-00131-x
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
dc.relation.isPartOfClinical sarcoma research
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamCancer Genomics
dc.contributor.icrauthorSlater, Susanna
dc.contributor.icrauthorCojocaru, Elena


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/